Fidelity Investments’s SpringWorks Therapeutics SWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-19,230
Closed -$904K 5577
2025
Q2
$904K Sell
19,230
-11,185,569
-100% -$498M ﹤0.01% 2755
2025
Q1
$494M Buy
11,204,799
+46,839
+0.4% +$2.16M 0.03% 458
2024
Q4
$403M Buy
11,157,960
+17,014
+0.2% +$594K 0.02% 560
2024
Q3
$357M Buy
11,140,946
+28,555
+0.3% +$1.07M 0.02% 600
2024
Q2
$419M Buy
11,112,391
+44,365
+0.4% +$1.87M 0.03% 508
2024
Q1
$545M Buy
11,068,026
+258,791
+2% +$12M 0.04% 428
2023
Q4
$395M Buy
10,809,235
+1,423,764
+15% +$37.2M 0.03% 494
2023
Q3
$214M Buy
9,385,471
+6,956
+0.1% +$190K 0.02% 670
2023
Q2
$243M Buy
9,378,515
+3,698
+0% +$97.2K 0.02% 651
2023
Q1
$238M Buy
9,374,817
+14,727
+0.2% +$430K 0.02% 641
2022
Q4
$240M Sell
9,360,090
-70
-0% -$1.73K 0.02% 623
2022
Q3
$263M Buy
9,360,160
+1,948,120
+26% +$55.9M 0.03% 576
2022
Q2
$182M Buy
7,412,040
+1,365,831
+23% +$49.9M 0.02% 729
2022
Q1
$341M Buy
6,046,209
+2,099,889
+53% +$120M 0.03% 574
2021
Q4
$245M Sell
3,946,320
-68,800
-2% -$4.55M 0.02% 722
2021
Q3
$255M Buy
4,015,120
+46,900
+1% +$3.61M 0.02% 701
2021
Q2
$327M Buy
3,968,220
+176,852
+5% +$13.4M 0.03% 619
2021
Q1
$279M Buy
3,791,368
+413,348
+12% +$32.4M 0.02% 644
2020
Q4
$245M Buy
3,378,020
+1,808,508
+115% +$116M 0.02% 665
2020
Q3
$74.8M Buy
1,569,512
+825,400
+111% +$35.2M 0.01% 1052
2020
Q2
$31.3M Sell
744,112
-157,300
-17% -$5.6M ﹤0.01% 1362
2020
Q1
$24.3M Sell
901,412
-209,700
-19% -$6.84M ﹤0.01% 1322
2019
Q4
$42.8M Hold
1,111,112
﹤0.01% 1274
2019
Q3
$24.1M Buy
+1,111,112
New +$26.3M ﹤0.01% 1499

Other funds holding SWTX

Fidelity Investments's SWTX Position: Q3 2025 in Review

Fidelity Investments sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 19,230 shares — an estimated $904K sold.

Fidelity Investments first reported a position in SWTX in Q3 2019 and held it in 24 quarters. The position peaked at $545M in Q1 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Fidelity Investments reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Fidelity Investments sold 19,230 SpringWorks Therapeutics shares in Q3 2025, an estimated $904K.
  • Fidelity Investments first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 24 quarters.
  • Fidelity Investments's SpringWorks Therapeutics position peaked at $545M in Q1 2024.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.